SEC Form 4 · accession 0000950142-15-002576
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Andrew N Schiff
10% Owner
Steve Elms
Director · 10% Owner
Dennis J Purcell
10% Owner
AISLING CAPITAL III LP
10% Owner
Aisling Capital Partners III LP
10% Owner
Aisling Capital Partners III LLC
10% Owner
Period of report
Dec 9, 2015
Accepted (ET)
Dec 9, 2015 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 9, 2015 | P | 307,692 | $9.75 | A | 2,830,992 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reportable securities are owned directly by Aisling Capital III, LP ("Aisling"), and held indirectly by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP. Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.